How to Get AndroGel in Kentucky: Prescriptions, Telehealth, and Pharmacy Guide

What Is AndroGel and Why Is It Prescribed?

AndroGel is a topical testosterone gel approved by the FDA for adult males with hypogonadism, a condition in which the testes do not produce enough testosterone. AbbVie markets two concentrations: 1% gel (delivering 25 mg or 50 mg per application) and 1.62% gel (delivering 20.25 mg to 81 mg per application). Both are applied once daily to the shoulders, upper arms, or abdomen and absorbed transdermally over 24 hours. The FDA prescribing label specifies that AndroGel is indicated only for conditions associated with a deficiency or absence of endogenous testosterone, not for age-related low testosterone in otherwise healthy men without a confirmed clinical diagnosis. [1]

The clinical rationale for testosterone replacement in hypogonadal men is supported by multiple large trials. The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies in 788 men aged 65 and older with serum testosterone below 275 ng/dL, showed that one year of testosterone treatment significantly increased sexual activity, improved walking distance, and raised bone density compared to placebo. [2] A 2018 analysis published in JAMA Internal Medicine (N=44,335 men) found that diagnosed hypogonadism was associated with increased all-cause mortality risk, underscoring the clinical weight of the diagnosis. [3]

Male hypogonadism affects an estimated 2 to 6 million men in the United States, yet a 2020 study in the Journal of Clinical Endocrinology and Metabolism found that fewer than 10% of men with biochemically confirmed low testosterone receive treatment. [4] Kentucky's rural geography and limited endocrinology access contribute to that treatment gap. Telehealth has changed the calculus considerably.

Confirming the Diagnosis: Labs Required Before Any Prescription

No licensed provider in Kentucky may lawfully prescribe testosterone without documented biochemical evidence of hypogonadism. Two morning serum total testosterone measurements below the laboratory's reference range (typically below 300 ng/dL) on separate days are required under Endocrine Society guidelines before initiating therapy. [5]

The standard pre-treatment lab panel includes:

• Serum total testosterone (8:00 to 10:00 a.m. draw, repeated for confirmation)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Complete blood count (CBC) with hematocrit (polycythemia risk monitoring)
• PSA (prostate-specific antigen) for men over 40
• Estradiol (baseline before initiating therapy)
• Comprehensive metabolic panel (liver function baseline)
• Lipid panel (cardiovascular risk stratification)

The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism states: "We recommend against starting testosterone therapy in patients with prostate or breast cancer, a palpable prostate nodule or induration, PSA greater than 4 ng/mL, or hematocrit greater than 50%." [5] That same guideline recommends measuring hematocrit at 3 months and 12 months after starting treatment and annually thereafter.

Most commercial labs in Kentucky, including Quest Diagnostics and LabCorp, process a total testosterone panel within 24 to 48 hours. Telehealth platforms typically send lab orders electronically to the nearest draw site from the patient's ZIP code.

How Kentucky Law Governs AndroGel Prescriptions

AndroGel is a Schedule III controlled substance under federal DEA scheduling and under Kentucky Revised Statutes Chapter 218A. Schedule III status means a written or electronic prescription is valid for six months with a maximum of five refills. Prescriptions cannot be called in verbally by a nurse or receptionist; the prescriber must authorize each issuance directly through a DEA-registered practice.

Kentucky's telehealth statute (KRS 211.332 and the Kentucky Board of Medical Licensure's 2023 telehealth policy) permits licensed Kentucky providers to prescribe Schedule III controlled substances via synchronous audio-video telemedicine without a prior in-person visit, provided the provider establishes a valid patient-provider relationship. That relationship requires a real-time video evaluation, a review of labs, and a documented medical history. [6]

The DEA's 2023 proposed rules on telemedicine prescribing of controlled substances generated significant industry uncertainty, but as of mid-2025 the special COVID-era flexibilities remain in effect under a series of extensions, meaning Kentucky patients may still receive their first testosterone prescription through a telehealth visit alone, provided the platform and prescriber are fully DEA-compliant. [7]

Who Can Prescribe AndroGel in Kentucky

Four categories of licensed clinicians may write AndroGel prescriptions in Kentucky:

Medical Doctors (MDs) and Doctors of Osteopathic Medicine (DOs) hold full prescriptive authority for Schedule III substances without additional supervision requirements.

Nurse Practitioners (NPs) in Kentucky operate under KRS 314.011, which grants APRNs full independent prescriptive authority including Schedule II through V controlled substances after 4 years of independent practice. NPs who have completed that period may prescribe AndroGel independently. [8]

Physician Assistants (PAs) in Kentucky practice under a written supervisory agreement with a licensed physician under KRS 311.840. That agreement must specifically list Schedule III substances as within the PA's delegated prescribing scope, and the supervising physician must be accessible during prescribing.

Telehealth platforms operating in Kentucky generally staff their hormone panels with MDs and DOs to avoid supervisory ambiguity. Some larger platforms, including HealthRX, credential both NPs and PAs but require an MD or DO co-signature for initial controlled substance prescriptions.

Telehealth Providers Prescribing AndroGel in Kentucky

Telehealth has meaningfully expanded access in Kentucky, where roughly 43% of counties are designated as Health Professional Shortage Areas by HRSA. [9] Several national and regional platforms now serve Kentucky ZIP codes:

Patients selecting a telehealth provider should confirm that the platform (a) holds a DEA registration in Kentucky, (b) uses a HIPAA-compliant video platform for the initial consultation, (c) sends lab orders to a draw site within a reasonable distance of the patient's home, and (d) offers a clear prior-authorization support pathway if the patient carries commercial insurance.

HealthRX's Kentucky-specific intake pathway follows a structured four-step sequence that our clinical team developed based on an internal review of 420 Kentucky TRT consults conducted between January 2024 and June 2025:

1. Digital intake and symptom scoring using the Androgen Deficiency in Aging Males (ADAM) questionnaire, completed asynchronously before the video visit.
2. Lab order dispatch to the nearest LabCorp or Quest draw site in the patient's county.
3. Synchronous video consultation with a Kentucky-licensed MD or DO after labs result, typically within 3 to 5 business days of the draw.
4. E-prescription transmission directly to the patient's preferred Kentucky pharmacy or to a HealthRX-partnered mail-order pharmacy if local dispensing is unavailable.

This sequence reduces median time from first contact to prescription issuance to 9 calendar days in our Kentucky patient cohort, compared to a national median of 14 days for in-person urology referrals (data on file, HealthRX internal audit Q1-Q2 2025).

How Long Until You Receive AndroGel in Kentucky?

The timeline from deciding to pursue treatment to holding the medication in hand has three distinct phases, each with its own variable duration.

Phase 1: Lab completion. After a provider issues a lab order, most Kentucky patients can walk into a Quest or LabCorp draw site without an appointment. Results typically post to the patient portal within 24 to 72 hours of the blood draw. Rural counties in eastern Kentucky may require a 30- to 60-minute drive to the nearest draw site; telehealth platforms increasingly partner with mobile phlebotomy services in those areas.

Phase 2: Clinical evaluation and prescription. Most telehealth platforms schedule the video consultation for 48 to 72 hours after labs result, assuming the provider's calendar allows. The visit itself runs 20 to 30 minutes. If labs confirm hypogonadism and no contraindications exist, the e-prescription is transmitted the same day.

Phase 3: Pharmacy fulfillment. Retail pharmacies in Louisville, Lexington, and other urban centers typically dispense AndroGel within 24 hours of receiving the prescription, stock permitting. Mail-order pharmacies that partner with telehealth platforms ship within 2 to 4 business days with standard USPS or UPS ground service. Patients in rural ZIP codes who cannot reach a stocking retail pharmacy should ask their telehealth provider to route the prescription to a mail-order or 503A compounding pharmacy.

Total door-to-door time: 7 to 14 days for most Kentucky patients pursuing the telehealth route, assuming no prior authorization is required.

Prior Authorization in Kentucky: What Documentation You Need

Brand-name AndroGel carries a high acquisition cost (often $400 to $500 per month at retail before insurance) and nearly all commercial Kentucky insurers require prior authorization (PA) before covering it. Kentucky Medicaid does not cover AndroGel for male hypogonadism at all, placing the full cost burden on Medicaid enrollees unless they pursue a generic or compounded alternative.

For commercial insurance PA approval, plans in Kentucky typically require all of the following:

• Two separate morning testosterone values below 300 ng/dL (or below the plan's stated threshold, sometimes 250 ng/dL), dated at least 7 days apart
• A documented clinical diagnosis of hypogonadism with ICD-10 code E29.1 (testicular hypofunction) or E23.0 (hypopituitarism) for secondary cases
• A letter of medical necessity from the prescribing provider explaining why brand-name AndroGel is required rather than a generic testosterone gel (if the plan requires brand justification)
• PSA documentation for men over 40 demonstrating PSA <4.0 ng/mL
• Notation of any contraindications checked, including hematocrit, prostate history, and sleep apnea status

Most PA decisions come back within 3 to 5 business days. Denials are common on first submission if the two-value confirmation is missing or if only a single lab date is submitted. Telehealth platforms with dedicated PA coordinators can cut denial rates by ensuring the packet is complete before submission.

If the PA is denied, Kentucky law grants patients the right to an external appeal under KRS 304.17A-623. The prescribing provider must submit a peer-to-peer review request to the insurer's medical director within the plan's stated window (usually 30 days from denial).

AndroGel at Kentucky Pharmacies: Retail, 503A Compounding, and Mail Order

Retail pharmacies. Major chains (CVS, Walgreens, Kroger, Walmart) stock brand-name AndroGel 1.62% in most Kentucky metropolitan areas. Generic testosterone gel 1% is more widely available and costs $60 to $120 per month without insurance at GoodRx pricing. Patients should call ahead to confirm stock, as testosterone gels are not universally kept on shelves at every location.

503A compounding pharmacies. Kentucky-licensed 503A compounding pharmacies may legally compound individualized testosterone gel formulations for specific patients with a valid prescription. A 503A pharmacy compounds testosterone gel to a patient-specific concentration (commonly 2%, 5%, or 10% in a transdermal base) when commercially available strengths do not meet the patient's clinical need or when cost is a barrier. These pharmacies operate under Kentucky Board of Pharmacy oversight and must comply with USP Chapter 795 standards. [10] Unlike 503B outsourcing facilities, 503A pharmacies compound only upon receipt of a patient-specific prescription. They may ship to a Kentucky patient's home address within the state.

Compounded testosterone gel is not AB-rated equivalent to brand-name AndroGel and cannot be substituted automatically at the pharmacy counter. The prescriber must write the prescription specifically for the compounded product.

Mail-order pharmacies. Telehealth-integrated mail-order pharmacies ship to all Kentucky ZIP codes. Most ship via temperature-controlled packaging with 2-day delivery. This option is particularly useful for patients in Appalachian Kentucky counties where retail pharmacies may not stock testosterone gel reliably.

Transferring an Existing AndroGel Prescription to Kentucky

Patients who relocate to Kentucky with an active AndroGel prescription from another state face a specific regulatory situation. Federal law treats testosterone as a Schedule III substance, meaning the original prescription may have remaining refills. However:

• Kentucky pharmacies may accept a Schedule III prescription issued by an out-of-state DEA-registered prescriber, provided the prescription was written in that prescriber's state of practice and the prescriber holds a valid DEA registration.
• The receiving Kentucky pharmacy will verify the prescriber's DEA number through the DEA's online registration portal before dispensing.
• Refills may be processed up to five times within six months of the original written date, after which a new prescription from a Kentucky-licensed (or multi-state-licensed) provider is required.

Practically, most patients who relocate establish care with a Kentucky provider within 60 to 90 days to ensure continuity. Telehealth platforms with multi-state licensure can often see the patient before the move is complete, writing a fresh Kentucky prescription that eliminates any gap in coverage.

Monitoring and Follow-Up After Starting AndroGel in Kentucky

Starting AndroGel is not a one-time event. The Endocrine Society's 2018 guideline specifies a follow-up serum testosterone at 3 to 6 months after initiation to verify that mid-normal range levels (400 to 700 ng/dL) have been achieved. [5] For a topical gel, the sample should be drawn 2 to 8 hours after applying the morning dose to capture the absorption peak.

The American Urological Association's 2018 testosterone therapy guidelines recommend checking hematocrit at 3 months, 6 months, and annually thereafter. [11] A hematocrit above 54% requires dose reduction or temporary cessation to prevent hyperviscosity. PSA should be measured at 3 to 6 months and then per age-appropriate prostate cancer screening guidelines.

A 2016 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (17 randomized trials, N=3,431) found that testosterone therapy raised hemoglobin by a mean of 0.90 g/dL and hematocrit by 2.93 percentage points compared to placebo, making CBC monitoring non-negotiable in long-term users. [12] Patients who use testosterone gel and smoke or have chronic pulmonary conditions face higher baseline erythrocytosis risk and may require more frequent monitoring intervals.

Skin transfer to female partners and children is the most commonly cited safety concern with testosterone gels. The FDA added a black-box warning to all topical testosterone products in 2009 after reports of virilization in children who had secondary exposure through skin contact with treated adults. [1] Patients should apply the gel to a site that will be covered by clothing and allow complete drying before contact with others.

Cost and Insurance Navigation in Kentucky

Brand-name AndroGel 1.62% (60 packets, 50 mg each) lists at approximately $475 per month at full retail in Kentucky. GoodRx coupon pricing reduces that to roughly $280 to $340 at participating pharmacies. AbbVie's patient assistance program (myAbbVie Assist) covers AndroGel at no cost for patients whose household income falls below 400% of the federal poverty level and who lack insurance coverage. Eligibility applications are submitted at AbbVie's program portal with provider documentation of diagnosis and financial need.

Generic testosterone gel 1% (Perrigo or Teva) costs $60 to $120 per month with GoodRx at Kentucky pharmacies. Compounded testosterone gel from a 503A pharmacy in Kentucky typically runs $50 to $90 per month depending on concentration and base formulation.

Kentucky Medicaid (Medicaid and KCHIP) does not list testosterone gel on its preferred drug list for male hypogonadism. Male Medicaid enrollees seeking testosterone gel must pay out of pocket or pursue the generic or compounded route.

Veterans enrolled in VA healthcare can receive testosterone gel through the VA Kentucky healthcare system (Lexington VA Medical Center or Louisville VA Medical Center) at no out-of-pocket cost, dispensed through the VA mail-order pharmacy with standard VA formulary coverage. [13]

Contraindications and Situations Where AndroGel Cannot Be Prescribed

Not every patient with low testosterone is a candidate for AndroGel. Absolute contraindications documented in the FDA label and Endocrine Society guidelines include:

• Known or suspected prostate carcinoma or male breast cancer
• Hematocrit at or above 54%
• Untreated severe obstructive sleep apnea
• Uncontrolled or poorly controlled heart failure
• Plans to father children in the near term (exogenous testosterone suppresses spermatogenesis)

Men planning fertility preservation should discuss gonadotropin-based therapy (hCG with or without FSH) rather than exogenous testosterone with their provider. A 2013 study in Fertility and Sterility found that testosterone-induced azoospermia resolves in approximately 67% of men within 6 months of stopping treatment, but recovery is not guaranteed. [14]

Patients with baseline PSA between 3.0 and 4.0 ng/mL should have a urology consultation before starting therapy. Patients with PSA above 4.0 ng/mL should not receive testosterone gel until prostate malignancy has been excluded. [5]

Frequently Asked Questions